PARP1 and hematologic disorder: These are conflicting and currently limited to AML, and there is still much to uncover regarding its regulatory mechanisms, such as metabolic balancing of NAD+ and ATP, alternative activations of PARP-1 and epigenetic targets of PARylation, parthanatos holds the potential to emerge as a possible weapon against hematological malignancies [104].